All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network
The MPN Hub were pleased to speak to Jacqueline S. Garcia, Dana-Farber Cancer Institute, Boston, US, during the 61st American Society of Hematology (ASH) meeting in Orlando, US. We asked: Can navitoclax plus ruxolitinib induce clinically relevant responses in patients with myelofibrosis?
Jacqueline S. Garcia comprehensively discusses a phase II clinical trial that added the BH3 mimetic, navitoclax, to ruxolitinib treatment in patients with myelofibrosis to increase patient response rate with this combination. She discusses the patient inclusion criteria, treatment regimen, safety, response rates, primary endpoints and overall outcome to this novel combination. She concludes by stating that this novel combination looks to be highly encouraging in producing clinically meaningful outcomes.
Can navitoclax plus ruxolitinib induce clinically relevant responses in patients with myelofibrosis?
MANIFEST study: Should CPI-0610 be used as an add-on to ruxolitinib in patients with advanced MF?
The MPN Hub were pleased to speak to John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US, during the 61st American Society of...
Is pacritinib safe and efficacious for patients with MF who failed ruxolitinib?
The MPN Hub were pleased to speak to Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, US, during the 61st American Society of Hematology (ASH) meeting...
Subscribe to get the best content related to MPN delivered to your inbox